GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Long Term F/U Studies at Y5&6 to Demonstrate the Equivalence of 2 Vaccination Schedules of Combined Hepatitis A & B Vaccine
Phase 3
Completed
- Conditions
- Hepatitis BHepatitis A
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2016-09-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 143
- Registration Number
- NCT00197171
- Locations
- 🇦🇺
GSK Investigational Site, Melbourne, Victoria, Australia
Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18
Phase 3
Completed
- Conditions
- Infections, Papillomavirus
- Interventions
- Biological: Cervarix
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2019-12-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 667
- Registration Number
- NCT00196937
- Locations
- 🇵🇱
GSK Investigational Site, Poznan, Poland
Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children
Phase 3
Completed
- Conditions
- Hepatitis A
- Interventions
- Biological: Havrix®Biological: M-M-R®IIBiological: VARIVAX®
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2018-07-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1474
- Registration Number
- NCT00197015
- Locations
- 🇺🇸
GSK Investigational Site, Marshfield, Wisconsin, United States
Human Papilloma Virus Vaccine Safety and Immunogenicity Trial in Young Adolescent Women With GSK Bio HPV-16/18.
Phase 3
Completed
- Conditions
- Infections, Papillomavirus
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 2067
- Registration Number
- NCT00196924
- Locations
- 🇨🇳
GSK Investigational Site, Tao Yuan County, Taiwan
Lot-to-lot Consistency of Tritanrix™-HepB/Hib-MenAC & Its Non-inferiority vs Tritanrix™-HepB/Hiberix™ in Infants
Phase 3
Completed
- Conditions
- Hepatitis BHaemophilus Influenzae Type bTetanusWhole Cell PertussisDiphtheria
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 800
- Registration Number
- NCT00197275
- Locations
- 🇹🇭
GSK Investigational Site, Songkla, Thailand
Comparison of Monodose and Multidose Presentations of GSK Biologicals' Hepatitis B Vaccine in Terms of Immune Response
Phase 4
Completed
- Conditions
- Hepatitis B
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2016-09-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 280
- Registration Number
- NCT00197158
- Locations
- 🇧🇪
GSK Investigational Site, Wilrijk, Belgium
Comparative Study in Healthy Adults Aged 18-50 Yrs Administered With Hepatyrix or Havrix+Typherix or Tiphim Vi, to Compare Reactogenicity & Immunogenicity
Phase 3
Completed
- Conditions
- Hepatitis A
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2016-09-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1034
- Registration Number
- NCT00197249
Evaluate 4 Different Formulations of Meningococcal Serogroups A, C, W-135, Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs
Phase 2
Completed
- Conditions
- Infections, Meningococcal
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2016-09-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 125
- Registration Number
- NCT00196963
- Locations
- 🇧🇪
GSK Investigational Site, Thuin, Belgium
Study to Evaluate Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 18-25 Years
Phase 2
Completed
- Conditions
- Infections, Meningococcal
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2016-09-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 50
- Registration Number
- NCT00196950
- Locations
- 🇧🇪
GSK Investigational Site, Gosselies, Belgium
Long Term Follow-up Study at Years 2, 3, 4 and 5 Where 2 Dosing Schedules of the Combined Hepatitis A and B Vaccine Were Compared
Phase 3
Completed
- Conditions
- Hepatitis BHepatitis A
- Interventions
- Biological: Twinrix™ AdultBiological: Twinrix™ Junior
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2018-08-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 276
- Registration Number
- NCT00197184
- Locations
- 🇪🇸
GSK Investigational Site, Valencia, Spain
© Copyright 2025. All Rights Reserved by MedPath